[go: up one dir, main page]

GT199800083A - Agonistas de prostaglandinas. - Google Patents

Agonistas de prostaglandinas.

Info

Publication number
GT199800083A
GT199800083A GT199800083A GT199800083A GT199800083A GT 199800083 A GT199800083 A GT 199800083A GT 199800083 A GT199800083 A GT 199800083A GT 199800083 A GT199800083 A GT 199800083A GT 199800083 A GT199800083 A GT 199800083A
Authority
GT
Guatemala
Prior art keywords
agonists
prostaglandin agonists
prostaglandin
bone
restore
Prior art date
Application number
GT199800083A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT199800083A publication Critical patent/GT199800083A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/28—Halogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/20—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 hydrogenated in the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/54—Radicals substituted by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

ESTA INVENCION SE REFIERE A AGONISTAS DE PROSTAGLANDINAS, A COMPOSICIONES FARMACEUTICAS QUE CONTIENEN DICHOS AGONISTAS PARA PREVENIR LA PERDIDA OSEA O RESTAURAR O AUMENTAR LA MASA OSEA, INCLUYENDO EL TRATAMIENTO DE AQUELLOS TRASTORNOS EN LOS QUE SE PRODUCE PERDIDA OSEA EN MAMIFEROS, INCLUYENDO EL SER HUMANO. ESTOS COMPUESTOS TIENEN LA ESTRUCTURA QUIMICA ( I ), EN LA QUE A, B, K, L, M, Q Y Z, SON GRUPOS FUNCIONALES DESCRITOS EN EL EXPEDIENTE.
GT199800083A 1997-06-23 1998-06-18 Agonistas de prostaglandinas. GT199800083A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5057597P 1997-06-23 1997-06-23

Publications (1)

Publication Number Publication Date
GT199800083A true GT199800083A (es) 1999-12-10

Family

ID=21966050

Family Applications (1)

Application Number Title Priority Date Filing Date
GT199800083A GT199800083A (es) 1997-06-23 1998-06-18 Agonistas de prostaglandinas.

Country Status (11)

Country Link
US (1) US6531485B2 (es)
AP (1) AP9801269A0 (es)
AR (1) AR013118A1 (es)
AU (1) AU7349298A (es)
CO (1) CO5080735A1 (es)
GT (1) GT199800083A (es)
HR (1) HRP980356A2 (es)
MA (1) MA26514A1 (es)
PA (1) PA8452701A1 (es)
TN (1) TNSN98104A1 (es)
WO (1) WO1998058911A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ513825A (en) 1999-03-05 2001-09-28 Procter & Gamble C 16 unsaturated FP-selective prostaglandins analogs
US6894175B1 (en) 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
DK1132086T3 (da) 2000-01-31 2006-08-28 Pfizer Prod Inc Anvendelse af prostaglandin (PGE2) selektive receptor 4 (EP4) agonister til behandling af akut og kronisk nyresvigt
US20010056060A1 (en) * 2000-02-07 2001-12-27 Cameron Kimberly O. Treatment of osteoporsis with EP2/EP4 receptor selective agonists
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
DE60323631D1 (de) * 2002-05-29 2008-10-30 Dsm Ip Assets Bv Verfahren zur reinigung einer rhizomucor aspartat-protease
JP2006021998A (ja) * 2002-07-18 2006-01-26 Ono Pharmaceut Co Ltd Ｅｐ２アゴニストを有効成分とする月経困難症治療剤
DK2465537T3 (en) 2002-10-10 2016-09-19 Ono Pharmaceutical Co MICROSPHERE INCLUDING ONO-1301
JP4666257B2 (ja) 2003-07-25 2011-04-06 小野薬品工業株式会社 軟骨関連疾患治療剤
JP4893999B2 (ja) 2004-10-22 2012-03-07 小野薬品工業株式会社 吸入用医薬組成物
US7091231B2 (en) * 2004-12-10 2006-08-15 Allergan, Inc. 12-Aryl prostaglandin analogs
NZ555945A (en) 2005-01-14 2011-01-28 Allergan Inc Substituted cyclopentanes or cyclopentanones for the treatment of ocular hypertensive conditions
EP2494990A1 (en) 2005-06-03 2012-09-05 Ono Pharmaceutical Co., Ltd. Agent for regeneration and/or protection of nerves
GB0518494D0 (en) * 2005-09-09 2005-10-19 Argenta Discovery Ltd Thiazole compounds
US7323591B2 (en) 2006-01-10 2008-01-29 Allergan, Inc. Substituted cyclopentanes or cyclopentanones as therapeutic agents
US7429669B2 (en) * 2006-06-20 2008-09-30 Allergan, Inc. Therapeutic compounds
CA2657625C (en) * 2006-07-10 2016-06-21 Allergan, Inc. Therapeutic compounds
ES2549863T3 (es) * 2006-07-11 2015-11-02 Allergan, Inc. Derivados de ciclopentano como agentes antiglaucoma
EP2170345B1 (en) * 2007-07-03 2013-03-06 Allergan, Inc. Therapeutic substituted cyclopentanes for reducing intraocular pressure
US7737140B2 (en) * 2008-04-24 2010-06-15 Allergan, Inc. Therapeutic compounds
US8569349B2 (en) * 2008-05-09 2013-10-29 Allergan, Inc. Therapeutic compounds
WO2009140205A2 (en) 2008-05-15 2009-11-19 Allergan, Inc. Therapeutic substituted cyclopentanes
WO2014069401A1 (ja) 2012-10-29 2014-05-08 株式会社カルディオ 肺疾患特異的治療剤
US9968716B2 (en) 2013-10-15 2018-05-15 Ono Pharmaceutical Co., Ltd. Drug-eluting stent graft
WO2021215365A1 (ja) 2020-04-21 2021-10-28 クミアイ化学工業株式会社 メタン生成阻害剤組成物及びメタン生成の抑制方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3888905A (en) * 1969-02-17 1975-06-10 Searle & Co Prostaglandin intermediates and optically active isomers thereof
US3980700A (en) * 1971-10-07 1976-09-14 G. D. Searle & Co. Prostaglandin intermediates and optically active isomers thereof
DE2434133C2 (de) * 1974-07-12 1987-03-19 Schering AG, 1000 Berlin und 4709 Bergkamen 15,15-Äthylendioxy-Prostansäurederivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
GB1521688A (en) * 1974-11-01 1978-08-16 May & Baker Ltd Cyclopentane derivatives
US3932389A (en) 1974-12-11 1976-01-13 Pfizer Inc. 2-Descarboxy-2-(tetrazol-5-yl)-11-desoxy-15-substituted-.omega.-pentanorprostaglandins
US4197407A (en) 1977-03-30 1980-04-08 American Cyanamid Company Prostenoic acids and esters
US4097601A (en) * 1977-08-26 1978-06-27 Pfizer Inc. Bone deposition by 2-descarboxy-2-(tetrazol-5-yl)-11-dexosy-16-aryl prostaglandins
HN1996000101A (es) 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis

Also Published As

Publication number Publication date
AP9801269A0 (en) 1999-12-18
AR013118A1 (es) 2000-12-13
US6531485B2 (en) 2003-03-11
HRP980356A2 (en) 1999-02-28
WO1998058911A3 (en) 1999-03-18
CO5080735A1 (es) 2001-09-25
PA8452701A1 (es) 2000-05-24
AU7349298A (en) 1999-01-04
MA26514A1 (fr) 2004-12-20
TNSN98104A1 (fr) 2005-03-15
WO1998058911A2 (en) 1998-12-30
US20030008895A1 (en) 2003-01-09

Similar Documents

Publication Publication Date Title
GT199800083A (es) Agonistas de prostaglandinas.
GT199700141A (es) Prevencion de la perdida y restauracion de la masa osea por determinados agonistas de prostaglandinas.
GT199800106A (es) Azetidinas.
ES2183937T3 (es) Inhibidores de la adhesion celular.
GT199700089A (es) Derivados 6.6 o 6.7 -biciclicos sustituidos que contienen pirido o pirimido.
GT199800158A (es) Agonistas de prostaglandinas.
ES2045110T3 (es) Mejoras en o relacionadas con antagonistas de leucotrienos.
GT199700095A (es) Derivados 6,5-heterobiciclicos sustituidos.
BR9804437A (pt) Compostos para a osteoporose
ES2036194T3 (es) Derivados n-fosfonilmetoxialquilicos de bases de pirimidina y purina, metodos para su preparacion y composiciones farmaceuticas basadas en ellos, con actividad antivirica.
ES2186015T3 (es) Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol.
PA8484301A1 (es) Formulaciones farmaceuticas de liberacion controlada
BR9708114A (pt) Análogos xantona para o tratamento de doenças infecciosas.
ES2106042T3 (es) Inhibidores de la incorporacion de calcio.
GT199700104A (es) Procedimientos e intermedios para preparar derivados de cromanol sustituidos.
DE69814109D1 (de) 1,3-dihydroxy-20,20-dialkyl-vitamin d3 analoga
ES2039286T3 (es) Composicion a base de goma de diorganopolisiloxano que contiene yodo, para el tratamiento de aguas.
AR018867A1 (es) Composicion farmaceutica, uso de la composicion, estuche, uso de los compuestos para preparar la composicion y el estuche
ES2129893T3 (es) Dinucleosido-5',5'-pirofosfatos.
ES2193297T3 (es) Agentes que previenen el mal olor humano.
ES2082074T3 (es) 1,3-difenil-2-propin-1-onas.
PA8472101A1 (es) Combinaciones terapeuticas para la fragilidad musculo esquelectica
ES2052622T3 (es) Derivados de benzodioxol, compuestos que los comprenden y utilizacion de los mismos para la fabricacion de medicamentos.
GT199800147A (es) Tetrahidronaftalenos substituidos y compuestos analogos.
GT199800045A (es) Quinoxalinadionas.